Annovis Bio enters first patients into pivotal Phase 3 Alzheimer's study of buntanetap

Annovis Bio, Inc.

First two patients enrolled in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.
Trial is 18-month, randomized, placebo-controlled, double-blind with primary endpoints ADAS-Cog13 and ADCS-iADL.
Over 750 participants expected across ~100 US sites; FDA-approved protocol.
Company raised $21M gross from public offering of 5.25M units to fund initial 6 months; 12-month from warrant exercises.
CEO cites prior Phase 2/3 data showing cognitive improvement and no safety concerns.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.